Press release
Rising Multiple Myeloma Cases Fuel Growth In The Abecma Market: Key Factor Driving The Growth In The Abecma Market
Abecma Market
What Is the Projected Growth of the Abecma Market?
In the last few years, the abecma market size has seen a high compound annual growth rate (HCAGR) of XX%. The projections suggest a growth from $XX million in 2024 to $XX million in 2025, translating to a compound annual growth rate (CAGR) of XX%. This growth during the historic period owes itself to factors like the approval of abecma for relapsed/refractory multiple myeloma, developments in car t-cell therapy, rising cases of multiple myeloma, its high effectiveness in treatment-resistant cases, and an increase in research and development investments.
The market size of abcema is projected to experience an XX (FCAGR) increase in the upcoming years, predicted to reach $XX million in 2029 with a compound annual growth rate (CAGR) of XX%. The projected growth during the forecast period is due to factors including the increasing incidence of multiple myeloma, broadening approved indications, advancements in personalized healthcare, worldwide market development, enhanced production and cost lowering. Key trends during the forecast period comprises of accelerated adoption in preceding treatment lines, geographical market growth, tech improvements in car t-cell therapy, strategies for combination therapy, precision and personalized medicine, and a heightened emphasis on relapsed/refractory multiple myeloma.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19847
What Are the Different Abecma Market Segments?
The abecma market covered in this report is segmented -
1) By Indication: Multiple Myeloma; B-Cell Lymphoma (BCL); Acute Lymphoblastic Leukemia (ALL)
2) By End User: Adult; Geriatric
3) By Distribution Channel: Hospitals And clinics; Retail And Speciality Pharmacies; Online Pharmacies
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19847&type=smp
What Are the Primary Drivers Shaping the Abecma Market?
The escalating incidence of multiple myeloma is anticipated to boost the growth of the abecma market. Multiple myeloma, a form of blood cancer that impacts plasma cells, a kind of white blood cell in bone marrow, has seen increasing prevalence due to an aging population, advancements in diagnostic methods, and heightened disease awareness. Abecma, a CAR T-cell therapy, serves as a treatment for multiple myeloma by using genetically altered immune cells to detect and eradicate cancerous plasma cells. This presents a unique treatment method for individuals with relapsed or refractory disease variations. For example, in January 2024, the American Cancer Society, a non-profit organization in the US devoted to the eradication of cancer, projected a total of 35,780 myeloma cases, compared to 34,470 in 2022. Therefore, the increasing occurrence of multiple myeloma catalyzes the growth of the abecma market.
Which Companies Are Leading in the Abecma Market?
Major companies operating in the abecma market include Bristol-Myers Squibb
What Are the Major Trends Shaping the Adbry/Adtralza Market?
The Abecma market is witnessing a significant thrust towards developing cutting-edge therapies like the chimeric antigen receptor T cell (CAR T) therapy to improve patient results, target particular types of cancer with higher efficacy, and broaden the treatment choices for those with recurrent or resistant multiple myeloma. CAR T therapy, an enhanced version of immunotherapy, is predominantly employed to treat specific cancer types such as leukemia and lymphoma. The technique comprises the genetic modification of a patient's T cells (a variant of white blood cells) to efficiently recognize and eradicate cancer cells. In March 2024, Bristol Myers Squibb, a pharmaceutical company based in the US, secured the European Commission's (EC) consent for Abecma (idecabtagene vicleucel; ide-cel), a CAR T-cell therapy formulated to treat adults with relapsed and refractory multiple myeloma. This endorsement particularly targets individuals who have been through at least two previous therapies, involving an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody, and who have displayed disease progression post their last treatment.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/abecma-global-market-report
What Are the Top Revenue-Generating Geographies in the Abecma Market?
North America was the largest region in the abecma market in 2024. The regions covered in the abecma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Abecma Market?
2. What is the CAGR expected in the Abecma Market?
3. What Are the Key Innovations Transforming the Abecma Industry?
4. Which Region Is Leading the Abecma Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Multiple Myeloma Cases Fuel Growth In The Abecma Market: Key Factor Driving The Growth In The Abecma Market here
News-ID: 4058494 • Views: …
More Releases from The Business Research Company
Seed Treatment Fungicides Market to Grow at 9.3% CAGR, Reaching $3.15 Billion by …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Seed Treatment Fungicides Market Outlook: How is the Market Expected to Grow by 2025?
Over the past few years, the market for seed treatment fungicides has seen robust growth. Its market value is projected to rise from $2.07 billion in 2024 to $2.21 billion in 2025, signifying a compound annual…
Rheology Modifiers Market Growth to be Driven by Emerging Trends | $10.92 Billio …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Rheology Modifiers Industry?
There has been a consistent expansion in the size of the rheology modifiers market in the past few years. The market, which was worth $8.59 billion in 2024, is projected to increase to $8.89 billion in 2025, demonstrating a compound…
Polyurethane Foam Market to Record 8.4% CAGR Growth Through 2029 | Global Analys …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Polyurethane Foam Market Outlook: How is the Market Expected to Grow by 2025?
In recent years, the size of the polyurethane foam market has experienced substantial growth. It is projected to increase from a value of $54.27 billion in 2024 to $57.26 billion in 2025, indicating a compound annual growth…
Pharmaceutical Intermediates Market Size to Reach $46.04 Billion by 2029 | Growt …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Pharmaceutical Intermediates Industry?
There has been consistent growth in the market size of pharmaceutical intermediates over the past few years. The market is predicted to increase from a value of $33.37 billion in 2024, up to $34.95 billion in 2025, with a compound…
More Releases for Abecma
CAR-T (Chimeric Antigen Receptor T-cell) therapy Market Future Business Scope An …
CAR-T (Chimeric Antigen Receptor T-cell) therapy has transformed the landscape of cancer treatment, offering a personalized and targeted approach that reprograms a patient's T-cells to attack cancer cells. Initially developed for hematologic malignancies such as B-cell lymphoma and acute lymphoblastic leukemia (ALL), the therapy is now progressing rapidly into solid tumor applications and next-generation allogeneic platforms.
With its ability to induce long-lasting remissions, CAR-T therapy has driven rapid commercial adoption. In…
Abecma Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Gro …
What industry-specific factors are fueling the growth of the abecma market?
The surge in the incidence of multiple myeloma is predicted to boost the expansion of the abecma market in the future. Multiple myeloma, a blood cancer variant, impacts plasma cells that are a particular type of white blood cell present in the bone marrow. The growing incidence of multiple myeloma can be attributed to factors like the growing elderly population,…
Global BCMA-Targeted CAR-T Cell Therapy Market Poised for Unprecedented Growth, …
The worldwide demand for BCMA-targeted CAR-T Cell Therapy continues to surge, with market valuations estimated at $1.38 billion in 2024 and projected to reach $6.88 billion by 2031, growing at a CAGR of 25.0% from 2025 to 2031. This rapid expansion is driven by increasing demand for innovative cancer treatments, particularly for multiple myeloma, where current therapies leave significant unmet medical needs.
What is BCMA-Targeted CAR-T Cell Therapy?
BCMA-targeted Chimeric Antigen Receptor…
Comprehensive Abecma Market Insights: Forecasting Size, Growth, and Competitive …
"What Is the Expected Size and Growth Rate of the Abecma Market?
In the recent years, the abecma market has marked an $XX. The market is expected to see a rise from $XX million in 2024 to $XX million in 2025, reflecting a compound annual growth rate (CAGR) of $XX%. The historic growth can be credited to factors like the approval of abecma for dealing with relapsed/refractory multiple myeloma, advancements in…
Gene Therapy Market Size to Surpass US$ 10.1 billion by 2032, at 18.5% CAGR
The global gene therapy market is expected to be valued $1.55 billion USD in 2021. The market is predicted to grow at an 18.5% CAGR from 1.85 billion US dollars in 2022 to 10.1 billion US dollars by 2032.
The Gene Therapy market represents a revolutionary frontier in healthcare, promising novel approaches to treat and potentially cure genetic disorders. This article provides a comprehensive overview of the current state of the…
CAR T-Cell Therapy Market to be Worth $51.6 Billion by 2030 - Exclusive Report b …
According to a new market research report, 'CAR T-Cell Therapy Market by Brand (Abecma [idecabtagene vicleucel], Breyanzi [lisocabtagene maraleucel], Yescarta [axicabtagene ciloleucel]), Target Antigen (CD, BCMA, HER2, Indication (Lymphoma, ALL, AML, Multiple Myeloma) - Global Forecast to 2030,' published by Meticulous Research®, the CAR T-Cell therapy market is projected to reach $51.6 billion by 2030, at a CAGR of 43.3% from 2023 to 2030.
The well-known cancer treatments have been…
